Success Metrics

Clinical Success Rate
90.0%

Based on 9 completed trials

Completion Rate
90%(9/10)
Active Trials
0(0%)
Results Posted
22%(2 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_1
3
23%
Ph phase_2
8
62%
Ph phase_3
2
15%

Phase Distribution

3

Early Stage

8

Mid Stage

2

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
3(23.1%)
Phase 2Efficacy & side effects
8(61.5%)
Phase 3Large-scale testing
2(15.4%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

90.0%

9 of 10 finished

Non-Completion Rate

10.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

13

all time

Status Distribution
Completed(9)
Terminated(1)
Other(3)

Detailed Status

Completed9
unknown3
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
0
Success Rate
90.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (23.1%)
Phase 28 (61.5%)
Phase 32 (15.4%)

Trials by Status

unknown323%
completed969%
terminated18%

Recent Activity

0 active trials
Showing 5 of 13
unknownphase_1

Catumaxomab in Patients With Non-Muscle-Invasive Bladder Cancer Who Have Failed or Are Intolerant to BCG Vaccine

NCT04799847
unknownphase_3

Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis

NCT04222114
unknownphase_1

Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBC

NCT04819399
completedphase_2

Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites

NCT00326885
completedphase_2

Catumaxomab as a Consolidation Therapy in Patients With Ovarian Cancer in Second or Third Clinical Disease Remission

NCT01246440
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT04799847Phase 1

Catumaxomab in Patients With Non-Muscle-Invasive Bladder Cancer Who Have Failed or Are Intolerant to BCG Vaccine

Unknown
NCT04222114Phase 3

Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis

Unknown
NCT04819399Phase 1

Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBC

Unknown
NCT00326885Phase 2

Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites

Completed
NCT01246440Phase 2

Catumaxomab as a Consolidation Therapy in Patients With Ovarian Cancer in Second or Third Clinical Disease Remission

Completed
NCT01815528Phase 2

Feasibility and Clinical Activity of Initial Intraperitoneal Catumaxomab Followed by Chemotherapy in Patients With Recurrent Ovarian Cancer

Completed
NCT00464893Phase 2

Phase II Study With Catumaxomab in Patients With Gastric Cancer After Neoadjuvant CTx and Curative Resection

Completed
NCT01320020Phase 1

A Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer Patients

Terminated
NCT00822809Phase 3

CASIMAS: Catumaxomab Safety Phase IIIb Study With Intraperitoneal Infusion in Patients With Malignant Ascites Due to Epithelial Cancers

Completed
NCT01065246Phase 2

Safety Study of Second Intraperitoneal (I.P.) Infusion Cycle of Catumaxomab in Patients With Malignant Ascites

Completed
NCT00563836Phase 2

Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer

Completed
NCT00377429Phase 2

Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy

Completed
NCT00352833Phase 2

Safety and Efficacy Study With Catumaxomab in Patients After Curative Resection of a Gastric Adenocarcinoma

Completed

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13